Stock 2162 KEYMED BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Keymed Biosciences Inc.

Equities

2162

KYG5252B1023

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:00 2024-05-03 am EDT 		5-day change 1st Jan Change
35.6 HKD -1.66% Intraday chart for Keymed Biosciences Inc. +10.22% -27.49%
Apr. 30 Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA MT
Apr. 29 Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed
AQ
Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration
PR
AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
AQ
InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369
AQ
Keymed has been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect
PR
Keymed Bio Joins Hang Seng Family of Indexes
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2162 Stock
  4. News Keymed Biosciences Inc.
  5. Press Releases